Navigation Links
Cancer drug protects against diabetes
Date:1/9/2014

Very low doses of a drug used to treat certain types of cancer protect the insulin-producing cells in the pancreas and prevent the development of diabetes mellitus type 1 in mice. The medicine works by lowering the level of so-called sterile inflammation. The findings have been made by researchers from the University of Copenhagen, the Technical University of Denmark and the University of Southern Denmark working with researchers in Belgium, Italy, Canada, Netherlands and the USA.

"Diabetes is a growing problem worldwide. Our research shows that very low doses of anticancer drugs used to treat lymphoma so-called lysine deacetylase inhibitors can reset the immune response to not attack the insulin-producing cells. We find fewer immune cells in the pancreas, and more insulin is produced when we give the medicine in the drinking water to mice that would otherwise develop type 1 diabetes," says postdoc Dan Ploug Christensen, who is the first author on the article and responsible for the part of the experimental work carried out in Professor Thomas Mandrup-Poulsen's laboratory at the Department of Biomedical Sciences, University of Copenhagen.

The ground-breaking findings have just been published in the scientific journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

From mice to men

"This type of medicine is already being used against certain cancers, but we used doses which are 100 times lower than those used in cancer treatment and which have been shown to be safe in children with certain rheumatic diseases," says Thomas Mandrup-Poulsen.

"Our results are a step towards developing a preventive treatment for type 1 diabetes," says Dan Ploug Christensen. "It works by blocking the molecules that send the harmful inflammation signals into the insulin-producing cells. In doing so, it prevents the cells from producing a number of factors which contribute to destroying the cells when exposed to inflammation."

The researchers have subjected insulin-producing tissue from organ donors to the inflammation signals and shown that cancer medicine also delays the destruction of human cells. "The next step is clinical trials to test whether the drug also has an effect on people at risk of developing type 1 diabetes, for example close family members to patients with the disease," says Thomas Mandrup-Poulsen.

No cure is available for type 1 diabetes, which has to be treated with several insulin injections a day. In Denmark, the incidence of type 1 diabetes is increasing by approx. 3 per cent a year.


'/>"/>

Contact: Dan Ploug Christensen
dploug@sund.ku.dk
45-25-34-55-44
University of Copenhagen
Source:Eurekalert

Related biology news :

1. Researchers discover a tumor suppressor gene in a very aggressive lung cancer
2. Novel noninvasive therapy prevents breast cancer formation in mice
3. UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer
4. International team completes systematic, genomic study of cervical cancer
5. Breast cancer patients experience fewer side effects from anticancer drug when receiving acupuncture
6. A new role for milk: Delivering polyphenols with anti-cancer activity
7. The first cancer operation room with a navigator is created
8. New compound could reverse loss of muscle mass in cancer and other diseases
9. Role for sugar uptake in breast cancer revealed
10. Muscle-invasive and non-muscle invasive bladder cancers arise from different stem cells
11. Spontaneous fusion with macrophages empowers cancer cells to spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, Inc. ... on its oral peptide drug candidates, PTG-100 and ... the European Crohn,s and Colitis Organization (ECCO).  The ... Barcelona, Spain from February 15 – ... preclinical data on Protagonist drug candidates PTG-100 and ...
(Date:2/16/2017)... Ann Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... between 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 ... hosted by a MichBio member organization. They provide an opportunity to interact with peers, ...
(Date:2/16/2017)... MENLO PARK, Calif. and ... -- Longitude Capital, a private investment firm focused on ... today announced the promotion of Josh Richardson ... Richardson focuses on investments in biotechnology companies.  He ... and has played important roles in Longitude,s investments ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
Breaking Biology Technology: